Immunosuppressive polypeptides and nucleic acids
View Patent ↗The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.
1. An isolated or recombinant fusion protein comprising (a) a first polypeptide comprising the polypeptide sequence that has at least 96% identity to the polypeptide sequence of SEQ ID NO:36, and (b) a second polypeptide, wherein the second polypeptide comprises a human immunoglobulin (Ig) polypeptide, wherein the fusion protein has an ability to bind CD80 or CD86 or an extracellular domain of either CD80 or CD86, and/or an ability to inhibit a T cell immune response.
2. The fusion protein of claim 1 , wherein the fusion protein inhibits T cell activation or T cell proliferation or cytokine production.
3. The fusion protein of claim 1 , wherein the second polypeptide is fused directly to the first polypeptide.
4. The fusion protein of claim 1 , wherein the second polypeptide is fused to a linker amino acid sequence that is fused to the first polypeptide.
5. The fusion protein of claim 1 , wherein the second polypeptide is fused to the C-terminus of the first polypeptide.
6. The fusion protein of claim 1 , wherein the second polypeptide comprises one or more domains of an Ig heavy chain constant region.
7. The fusion protein of claim 1 , wherein the second polypeptide comprises a hinge region, CH2 domain, and CH3 domain of an Ig polypeptide.
8. The fusion protein of claim 1 , wherein the Ig polypeptide is a wild-type human Ig polypeptide.
9. The fusion protein of claim 8 , wherein the human Ig polypeptide is a human IgG polypeptide, which human IgG polypeptide is a human IgG2 polypeptide.
10. An isolated or recombinant fusion protein dimer comprising two monomeric fusion proteins linked via at least one disulfide bond formed between two cysteine residues present in each monomeric fusion protein, wherein each monomeric fusion protein comprises (a) a polypeptide comprising the polypeptide sequence having at least 96% identity to the polypeptide sequence of SEQ ID NO:36 and (b) a human immunoglobulin (Ig) polypeptide, wherein the fusion protein dimer has an ability to bind CD80, or CD86, or CD80-Ig, or CD86-Ig, and/or has an ability to inhibit or suppress a T cell immune response.
11. The fusion protein dimer of claim 10 , wherein the fusion protein dimer has a binding avidity for human CD86 or an extracellular domain thereof or hCD86-Ig that is greater than the binding avidity of a CTLA-4-IgG2 fusion protein dimer for human CD86 or an extracellular domain thereof or hCD86-Ig, respectively, wherein the CTLA-4-IgG2 fusion protein dimer comprises two monomeric CTLA-4-IgG2 fusion proteins, each monomeric CTLA-4-IgG2 fusion protein comprising the polypeptide sequence of SEQ ID NO:162.
12. A composition comprising an excipient or carrier and the fusion protein of claim 1 .
13. A composition comprising an excipient or carrier and the fusion protein dimer of claim 10 .
14. The fusion protein of claim 1 , wherein the first polypeptide comprises the sequence SEQ ID NO:36.
15. The fusion protein of claim 14 , comprising the sequences SEQ ID NO:211.
16. The fusion protein of claim 15 , consisting of the sequence SEQ ID NO:211 or SEQ ID NO: 197.
17. The fusion protein dimer of claim 10 , wherein the polypeptide in each monomeric fusion protein comprises the sequence SEQ ID NO:36.
18. The fusion protein dimer of claim 17 , wherein each monomeric fusion protein comprises the sequence SEQ ID NO:211.
19. An isolated or recombinant fusion protein dimer comprising two monomeric fusion proteins linked via at least one disulfide bond formed between two cysteine residues present in each monomeric fusion protein, wherein each monomeric fusion protein consists of the sequence SEQ ID NO:211 or SEQ ID NO:197, wherein the fusion protein dimer has an ability to bind CD80, or CD86, or CD80-Ig, or CD86-Ig, and/or has an ability to inhibit or suppress a T cell immune response.